- Home
- NTLA vs SANA Comparison
NTLA vs SANA Comparison
Compare NTLA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- SANA
- Stock Information
- Founded
- NTLA 2014
- SANA 2018
- Country
- NTLA United States
- SANA United States
- Employees
- NTLA N/A
- SANA N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SANA Medicinal Chemicals and Botanical Products
- Sector
- NTLA Health Care
- SANA Health Care
- Exchange
- NTLA Nasdaq
- SANA Nasdaq
- Market Cap
- NTLA 1.2B
- SANA 983.4M
- IPO Year
- NTLA 2016
- SANA 2021
- Fundamental
- Price
- NTLA $9.21
- SANA $4.06
- Analyst Decision
- NTLA Buy
- SANA Strong Buy
- Analyst Count
- NTLA 20
- SANA 7
- Target Price
- NTLA $23.53
- SANA $7.83
- AVG Volume (30 Days)
- NTLA 11.1M
- SANA 6.8M
- Earning Date
- NTLA 11-06-2025
- SANA 11-06-2025
- Dividend Yield
- NTLA N/A
- SANA N/A
- EPS Growth
- NTLA N/A
- SANA N/A
- EPS
- NTLA N/A
- SANA N/A
- Revenue
- NTLA $57,528,000.00
- SANA N/A
- Revenue This Year
- NTLA $8.51
- SANA N/A
- Revenue Next Year
- NTLA N/A
- SANA N/A
- P/E Ratio
- NTLA N/A
- SANA N/A
- Revenue Growth
- NTLA 33.52
- SANA N/A
- 52 Week Low
- NTLA $5.90
- SANA $1.26
- 52 Week High
- NTLA $28.25
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- NTLA 30.06
- SANA 41.41
- Support Level
- NTLA $12.15
- SANA $5.12
- Resistance Level
- NTLA $13.69
- SANA $5.00
- Average True Range (ATR)
- NTLA 1.51
- SANA 0.41
- MACD
- NTLA -1.34
- SANA -0.22
- Stochastic Oscillator
- NTLA 0.69
- SANA 19.33
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.